RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).

Wilke, H.; Van Cutsem, Eric; Cheul Oh, Sang; Bodoky, G.; Shimada, Yasuhiro; Hironaka, Shuichi; Sugimoto, Naotoshi; Lipatov, Oleg; Kim, Tae‐You; Cunningham, David; Ohtsu, Atsushi; Rougier, Philippe; Emig, Michael; Carlesi, Roberto; Chandrawansa, Kumari; Muro, Kei

doi:10.1200/jco.2014.32.3_suppl.lba7

Public

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).

Shared by NobleBlocks on Jan 20, 2014 • 12:00 AM UTC

Authors:

H. Wilke

Eric Van Cutsem

Sang Cheul Oh

Abstract

LBA7 Background: RAM is a human IgG1 monoclonal antibody VEGF-receptor 2 antagonist. We conducted a global, placebo-controlled, double-blind, phase III trial to evaluate the efficacy and safety of PTX +/- RAM in patients with metastatic GEJ or gastric adenocarcinoma who had disease progression on or...

Subject

Medicine

Ramucirumab

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!